Isolation of Acein-2, a novel angiotensin-I-converting enzyme inhibitory peptide derived from a tryptic hydrolysate of human plasma  by Nakagomi, Kazuya et al.
Isolation of Acein-2, a novel angiotensin-I-converting enzyme inhibitory
peptide derived from a tryptic hydrolysate of human plasma
Kazuya Nakagomia;*, Riho Yamadaa, Hidetoshi Ebisua, Yutaka Sadakanea,
Toshifumi Akizawab, Takenori Tanimuraa
aFaculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan
bFaculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata 570-0101, Japan
Received 27 December 1999
Edited by Gunnar von Heijne
Abstract We previously described a novel angiotensin-I-con-
verting enzyme (ACE) inhibitory peptide, designated Acein-1,
that was isolated from a tryptic hydrolysate of human plasma.
We now report a second such inhibitory peptide, Acein-2
obtained from the same hydrolysate. The peptide was purified
by gel filtration and cation exchange chromatography followed
by reversed-phase gradient and isocratic high performance liquid
chromatography. Acein-2 was found to be a tripeptide, Leu-Ile-
Tyr, which is thought to correspond to f(518^520) of human K2-
macroglobulin. The synthetic tripeptide showed a potent dose-
dependent inhibition of ACE, with an IC50 value of 0.82 Wmol/l.
Lineweaver^Burk plots suggested that Acein-2 as well as the
previously described Acein-1 are non-competitive inhibitors.
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1. Introduction
Almost all organisms, including animals, plants, and micro-
organisms, as well as synthetic compounds have been exam-
ined in the search for bioactive substances as starting materi-
als for medicines [1^7]. However, we believe that the human
body might be the best resource for such bioactive peptides
because such substances would be expected to be less toxic to
humans. Although numerous substances have been isolated
from the human body, there are probably many others, espe-
cially degradation products of proteins, that have not yet been
identi¢ed. To demonstrate this idea, we have isolated Acein-1
[8] and Cabin-1, 2, 3 and 4 [9] as novel bioactive peptides in
enzymatic hydrolysates of human plasma. Acein-1, a novel
peptide that inhibits angiotensin-I-converting enzyme (ACE,
peptidyl dipeptide hydrolase), was isolated from a tryptic hy-
drolysate of human plasma. The amino acid sequence of
Acein-1 (Tyr-Leu-Tyr-Glu-Ile-Ala-Arg) corresponds to
f(138^144) of human serum albumin. During the isolation of
Acein-1, another active fraction was found in the e¥uent from
a SP-Sephadex C-25 column.
In this paper, we report the isolation of another novel ACE
inhibitory peptide, which was derived from a tryptic hydro-
lysate of human plasma. We also discuss the inhibitory mech-
anism of Acein-2 based on Lineweaver^Burk plots.
ACE has classically been associated with the renin-angio-
tensin system, which regulates peripheral blood pressure. ACE
raises blood pressure by converting angiotensin-I, released
from angiotensinogen by renin, into the potent vasoconstric-
tor angiotensin-II. ACE also degrades vasodilative bradykinin
in blood vessels and stimulates the release of aldosterone in
the adrenal cortex. Consequently, ACE inhibitors may exert
an anti-hypertensive e¡ect [10,11].
2. Materials and methods
2.1. Enzymes and other reagents
Freshly frozen human plasma for use in transfusion was used. ACE
(EC 3.4.15.1, from rabbit lung) and trypsin (EC 3.4.21.4, from porcine
pancreas) were purchased from Wako Pure Chemicals (Osaka, Japan)
and Sigma Chemical (St. Louis, MO, USA), respectively. Hippuryl-
histidyl-leucine (HHL) and bradykinin potentiator B (BPB) were
obtained from The Peptide Institute (Osaka). Sephadex G-25 and
SP-Sephadex C-25 were from Pharmacia Biotech (Uppsala, Sweden),
and the SEP-PAK C18 cartridge was from Waters (Milford, MA,
USA). All other reagents were of analytical grade unless otherwise
speci¢ed.
2.2. Tryptic hydrolysis
Human plasma (10 ml) was diluted with seven volumes of 50 mM
Tris^HCl bu¡er (pH 8.0). Trypsin was added to the plasma solution
at an enzyme:substrate ratio of 1:50 and the mixture was hydrolyzed
at 37‡C for 3 h. The reaction was stopped by heating in boiling water
for 10 min, and the hydrolysate was centrifuged for 20 min at 4‡C and
3000Ug. The supernatant was used as a sample.
2.3. Sephadex G-25 gel ¢ltration
A sample of the supernatant was concentrated by 5-fold with a
vacuum concentrator, and 10 ml of the concentrate was applied di-
rectly to a Sephadex G-25 column (30 i.d.U360 mm) equilibrated with
10 mM ammonium acetate (pH 4.0). The same solution was used as
the eluent at a £ow rate of 3.6 ml/min. Fraction volume was 10 ml.
Fraction Nos. 18^22 were found to have activity.
2.4. SP-Sephadex C-25 cation exchange column chromatography
About 50 ml of the combined fractions from the gel ¢ltration was
applied to a SP-Sephadex C-25 cation exchange column (30 i.d.U420
mm) equilibrated with 10 mM ammonium acetate (pH 4.0). Materials
were eluted with a linear gradient between 250 ml of 10 mM ammo-
nium acetate (pH 4.0) and 250 ml of the same solution containing
500 mM ammonium formate and then 300 ml of the ¢nal solution at a
£ow rate of 3.0 ml/min. Fraction volume was 16 ml. Fraction Nos.
10^14, 34^38 and 42^45 were found to have activity. For each of these
three groups of fractions, the fractions were pooled, desalted with a
SEP-PAK C18 cartridge and concentrated.
2.5. Reversed-phase gradient high performance liquid chromatography
(HPLC)
The desalted samples were puri¢ed by HPLC with gradient elution.
A GILSON HPLC system was used with an autogradient set (Model
802, 803C, and two Model 302 pumps, GILSON Medical Electronics,
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Middleton, WI, USA). Separation was performed at room temper-
ature on a Develosil ODS-5 (Nomura Kagaku, Osaka, Japan) column
(4.0 i.d.U150 mm). A linear acetonitrile gradient between 0.1% tri-
£uoroacetic acid (TFA) in water (solvent A) and 80% acetonitrile with
0.1% TFA in water (solvent B) was used as follows: 0% B for 20 min,
0^40% B for 60 min, 40% B for 30 min and 100% B for 10 min. The
£ow rate was 1.0 ml/min and the e¥uent was monitored continuously
at 215 nm. All peaks were fractionated and evaporated for measuring
inhibitory activity.
2.6. Reversed-phase isocratic HPLC
The active fractions were further puri¢ed by reversed-phase iso-
cratic HPLC. The HPLC system used was the same as the gradient
HPLC system. Separation was performed on a single or a tandem-
linked Develosil ODS-5 column (4.0 i.d.U150 mm) at room temper-
ature. 18% Acetonitrile with 0.1% TFA was used as the eluent. The
£ow rate was 0.5 ml/min and the e¥uent was monitored continuously
at 215 nm. The active fractions were collected and evaporated.
2.7. Inhibitory assay for ACE
The inhibitory activity of ACE was measured spectrophotometri-
cally using HHL as the substrate, by a modi¢cation of the method of
Cushman and Cheung [12] as described by Maruyama et al. [13].
5 mM HHL and an appropriate quantity of ACE inhibitor were
dissolved in 100 mM sodium borate bu¡er, pH 8.3, containing
300 mM NaCl, and incubated with 20 mU/ml ACE at 37‡C for
30 min. The concentration of ACE inhibitors needed to inhibit 50%
of ACE activity was de¢ned as the IC50 value. BPB (IC50 = 3.3 WM)
was used as a positive control for ACE inhibition [14].
2.8. Amino acid sequence analysis and mass spectrometry
The amino acid sequence was determined using Edman degradation
on a pulsed-liquid protein sequencer, equipped with an on-line phe-
nylthiohydantoin amino acid analyzer (Shimadzu PPSQ-21, Kyoto,
Japan). A mass analysis of the peptides was carried out using a
mass spectrometer (JMS-AX505, JEOL, Tokyo, Japan).
2.9. Preparation of peptides [15]
Peptides were synthesized with the solid phase Fmoc method on a
peptide synthesizer (Applied Biosystems 433A, Foster City, CA, USA)
and deprotected in the usual manner. Puri¢cation was performed by
HPLC with a reversed-phase column (Capcell Pak C18, 10 i.d.U250
mm, Shiseido, Tokyo, Japan) employing a linear gradient elution
system from H2O to 50% acetonitrile containing 0.1% TFA for
30 min. The £ow rate was set for 3.0 ml/min. E¥uents were moni-
tored by UV absorption at 220 nm, and the peaks with 220 nm ab-
sorbance were collected and lyophilized.
2.10. Measurement of chymotryptic activity [16]
The chymotrypsin activity was measured by using N-benzoyl-Tyr
ethyl ester (BTEE) as the substrate. The reaction mixture consisted of
1.5 ml trypsin solution in 80 mM Tris^HCl bu¡er containing 100 mM
CaCl2 (pH 7.8) and 1.5 ml of 1.0 mM BTEE in 50% MeOH. The
reaction was started by adding the trypsin solution. The increase in
absorbance at 256 nm was measured at precisely 1, 2 and 3 min. The
chymotrypsin activity (BTEE U/l) was calculated from the following
formula: BTEE (U/l) = 31 100UvAbs/min.
3. Results and discussion
With the use of HHL as the substrate, the tryptic hydro-
lysate of human plasma after a 3 h incubation was found to
have signi¢cant ACE inhibitory activity. Fractions 18^22
from a Sephadex G-25 column showed ACE inhibition, while
the other fractions had no activity. About 50 ml of the com-
bined fractions was subjected to SP-Sephadex C-25 cation
exchange chromatography. Some of the SP-Sephadex C-25
cation exchange fractions were found to be active as shown
in Fig. 1. Acein-1, which was previously reported [8], was
found in fractions 42^45 (striped bars in Fig. 1), while frac-
tions 10^14 and fractions 34^38 (solid bars in Fig. 1) also
showed ACE inhibition. These fractions were collected and
concentrated through SEP-PAK C18 cartridges. The sample
from fractions 34^38 was puri¢ed by reversed-phase HPLC
with gradient elution (Fig. 2). The fraction that eluted at
around 18% acetonitrile (solid bars in Fig. 2) showed inhib-
itory activity. This fraction was rechromatographed using iso-
cratic HPLC (18% acetonitrile with 0.1% TFA) and isolated
as a single peak. The inhibitory activity in fractions 10^14 was
found to decrease after they were desalted and concentrated.
Amino acid sequencing analysis of the puri¢ed peptide
showed that it was a tripeptide with the sequence of Leu-
Ile-Tyr. The mass number of this peptide as determined by
mass spectrometry was 408.36 (M+H). This value was con-
sistent with the value calculated from the peptide sequence,
408.25. Mass peaks of 295.25 and 182.13 were simultaneously
observed, which were consistent with the calculated mass
numbers of Ile-Tyr, 295.17 (M+H) and Tyr, 182.08
(M+H), respectively. Moreover, the puri¢ed peptide was
identical to the synthetic tripeptide on isocratic HPLC analy-
sis. Consequently, the puri¢ed peptide was identi¢ed as the
tripeptide, Leu-Ile-Tyr, and designated Acein-2.
Acein-2, like Acein-1, was found to originate from human
plasma proteins by tryptic digestion, because no activity was
observed prior to the digestion. Leu-Ile-Tyr was not a tryptic
fragment because the C-terminal amino acid is Tyr, which
could not be generated by tryptic digestion. The chymotryptic
activity in the trypsin solution was examined, and was deter-
mined to be 2 BTEE U/mg protein. Thus, Leu-Ile-Tyr was a
product of chymotryptic activity, which contaminated the
commercial trypsin.
A protein database analysis was performed to ¢nd the orig-
inal protein that was hydrolyzed by trypsin (or chymotrypsin)
to release Acein-2. Numerous candidates that contained the
Leu-Ile-Tyr sequence were found because Acein-2 is only a
tripeptide. The most likely protein was human K2-macroglo-
bulin (K2M), which contains two Leu-Ile-Tyr sequences. K2M
is one of the major proteins in human plasma, with a concen-
tration of 2^5 mg/ml [17]. K2M is known to be part of the
body’s defense system that acts as a molecular trap for pro-
teinase molecules [18]. The amino acid sequence of Acein-2
was found to be identical to that of f(518^520) and f(1393^
1395) in K2M. We suggest that Acein-2 was derived from
Fig. 1. Fractionation of a tryptic hydrolysate of human plasma on
SP-Sephadex C-25. Active fractions eluted from the gel ¢ltration
column were applied to a SP-Sephadex C-25 cation exchange col-
umn (30 i.d.U420 mm) equilibrated with 10 mM CH3COONH4
(pH 4.0). Materials were eluted with a linear gradient formed with
250 ml of 10 mM CH3COONH4 (pH 4.0) and 250 ml of 10 mM
CH3COONH4 (pH 4.0) containing 500 mM HCOONH4, and then
300 ml of the ¢nal solution at a £ow rate of 3.0 ml/min. Dashed
line shows the concentration of HCOONH4 in the eluent. Fractions
(16 ml each) were collected and their absorbance at 280 nm was
measured. Fractions 34^38 (solid bars) contain Acein-2 and frac-
tions 42^45 (striped bars) contain Acein-1.
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f(518^520) of K2M by chymotryptic cleavage because the pre-
ceding residue is Leu. The other fragment f(1393^1395) was
probably not the source of Acein-2 because the preceding
residue is Val. The other candidates in human plasma for
the source of Acein-2 by either tryptic or chymotryptic diges-
tion were human apolipoprotein B-100, human tumor necrosis
factor K and the immunoglobulin V and U chain V-I regions.
The amino acid sequence of Acein-2 was identical to that of
f(4505^4507) in human apolipoprotein B-100, and to that of
f(57^59) in human tumor necrosis factor K, and both sequen-
ces could be digested by chymotryptic activity because the
preceding residues are Phe and Tyr, respectively. However,
it seems unlikely that Acein-2 is derived from hydrolysates
of these proteins because both proteins are minor components
in human plasma. Although human immunoglobulin V and U
chain V-I regions also contain Acein-2 sequences, these se-
quences occur in variable regions and thus are thought not
to be common. As a result, Acein-2 was thought to originate
from K2M.
Many bioactive peptides have been isolated from enzymatic
hydrolysates of proteins [19^24]. In addition to Acein-1, we
have isolated four novel inhibitory peptides from a thermo-
lytic hydrolysate of human plasma. These peptides, designated
Cabin-1, 2, 3 and 4, were found to be inhibitors of cathepsin
B. Cabin-1 (Leu-Gly-Pro-Val-Thr-Gln-Glu) corresponds to
f(64^70) of human apolipoprotein A-I, and Cabin-2 (Val-
Leu-Gln-Ser-Ser-Gly-Leu-Tyr-Ser) and Cabin-3 (Val-Val-Ser-
Val-Leu-Thr) correspond to f(56^64) and f(185^190) of the
human immunoglobulin G Q-chain, while Cabin-4 (Leu-Val-
Tyr-Asp-Ala-Tyr) corresponds to f(66^71) of human transfer-
rin [12]. On the other hand, L-casomorphin (Tyr-Pro-Phe-Pro-
Gly-Pro-Ile), an opioid peptide, was isolated from bovine ca-
sein by Brantl et al. [25]. Casoxin D (Tyr-Val-Pro-Phe-Pro-
Pro-Phe), a bradykinin agonist, was isolated from a peptic
and chymotryptic hydrolysate of human casein [26]. We be-
lieve that the human body might be the best resource for such
bioactive peptides because such substances would make good
starting materials for safer and less toxic medicines. Acein-2,
as well as Acein-1 and the Cabin peptides might be good
examples for demonstrating this idea.
The ACE inhibitory activity of synthetic Acein-2 was found
to be dose-dependent with an IC50 value of 0.82 Wmol/l (Fig.
3). This value was greater than the IC50 value of Acein-1 (16
Wmol/l).
Miyoshi et al. reported that some tripeptides isolated from
a hydrolysate of K-zein, a maize endosperm protein, act as
ACE inhibitors [27]. These peptides, Leu-Arg-Pro, Leu-Ser-
Pro, Leu-Gln-Pro and Leu-Ala-Tyr, had IC50 values of 0.27,
1.7, 1.9 and 3.9 Wmol/l, respectively. They also found that
Leu-Arg-Pro had a hypotensive activity, as a 30 mg/kg intra-
venous injection decreased the blood pressure of spontane-
ously hypertensive rats by 15 mm Hg. Matsumura et al. iso-
lated four ACE inhibitory peptides from an autolysate of
bonito bowels [28]. These peptides, Leu-Arg-Pro, Ile-Arg-
Pro, Val-Arg-Pro and Ile-Lys-Pro, had IC50 values of 1.0,
1.8, 2.2 and 2.5 Wmol/l, respectively. It should be noted that
peptides derived from food proteins such as K-zein have been
shown to have signi¢cant physiological e¡ects and have been
used in an attempt to prevent hypertension [20,27]. It is un-
known whether Acein-2 has a hypotensive activity in human
or rat. Further experiments are needed to answer this ques-
tion.
To clarify the inhibition mechanism kinetically, Linewea-
ver^Burk plots were determined for Acein-2 [29]. These plots
showed that it is a non-competitive inhibitor, with an inter-
cept on the 1/[S] axis as shown in Fig. 4. These plots suggested
that Acein-2 could not bind to the catalytic site of ACE and
that it could not be hydrolyzed by ACE. Acein-1 was also a
non-competitive inhibitor. Acein-2 might be able to enter the
catalytic site, but it did not bind due to the non-competitive
Fig. 2. Reversed-phase gradient HPLC chromatogram. Separation
was performed at room temperature on a Develosil ODS-5 column
(4.0 i.d.U150 mm). A linear acetonitrile gradient between 0.1%
TFA in water and 80% acetonitrile with 0.1% TFA in water is
shown as the dashed line. The £ow rate was 1.0 ml/min, and the ef-
£uent was monitored continuously at 215 nm. The solid bars indi-
cate the fractions with ACE inhibitory activity.
Fig. 3. Dose-dependent inhibition of ACE by Acein-2 (b) and
Acein-1 (a). Each point represents the mean value of three experi-
ments.
Fig. 4. Lineweaver^Burk plots of the inhibition of ACE by Acein-2.
Each point represents the mean value of three experiments. ACE ac-
tivities were measured in the absence (b) or in the presence of 0.5
Wmol/l (R) or 1.0 Wmol/l (F) of Acein-2.
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inhibition. These ¢ndings suggest that another explanation is
needed for the kinetic mechanism of Acein-2.
The present results suggest that Acein-2, as well as Acein-1,
could be used as a starting material for anti-hypertensive
drugs against ACE. It is not yet known whether Acein-2 is
released mainly from K2M by endogenous chymotryptic hy-
drolysis in the human body to inhibit ACE as part of the
physiological regulation.
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